IL156158A0 - Lactam compounds and pharmaceutical use thereof - Google Patents

Lactam compounds and pharmaceutical use thereof

Info

Publication number
IL156158A0
IL156158A0 IL15615801A IL15615801A IL156158A0 IL 156158 A0 IL156158 A0 IL 156158A0 IL 15615801 A IL15615801 A IL 15615801A IL 15615801 A IL15615801 A IL 15615801A IL 156158 A0 IL156158 A0 IL 156158A0
Authority
IL
Israel
Prior art keywords
diabetic
pharmaceutical use
lactam compounds
agent
adiposis
Prior art date
Application number
IL15615801A
Other languages
English (en)
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of IL156158A0 publication Critical patent/IL156158A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
IL15615801A 2000-12-01 2001-11-29 Lactam compounds and pharmaceutical use thereof IL156158A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000367175 2000-12-01
PCT/JP2001/010435 WO2002044180A1 (en) 2000-12-01 2001-11-29 Lactam compounds and medicinal use thereof

Publications (1)

Publication Number Publication Date
IL156158A0 true IL156158A0 (en) 2003-12-23

Family

ID=18837660

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15615801A IL156158A0 (en) 2000-12-01 2001-11-29 Lactam compounds and pharmaceutical use thereof

Country Status (26)

Country Link
US (3) US7153850B2 (de)
EP (1) EP1346993B1 (de)
JP (2) JP3826400B2 (de)
KR (1) KR100826818B1 (de)
CN (2) CN100577651C (de)
AT (1) ATE446297T1 (de)
AU (3) AU2002218502B2 (de)
BG (1) BG107857A (de)
BR (1) BR0115852A (de)
CA (1) CA2430124C (de)
CZ (1) CZ20031520A3 (de)
DE (1) DE60140270D1 (de)
ES (1) ES2331299T3 (de)
HU (1) HUP0400806A3 (de)
IL (1) IL156158A0 (de)
MX (1) MXPA03004876A (de)
NO (1) NO325401B1 (de)
NZ (1) NZ526164A (de)
PL (1) PL362835A1 (de)
RU (1) RU2287530C2 (de)
SK (1) SK6582003A3 (de)
TW (1) TWI241302B (de)
UA (1) UA76969C2 (de)
WO (1) WO2002044180A1 (de)
YU (1) YU42603A (de)
ZA (1) ZA200304100B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100577651C (zh) * 2000-12-01 2010-01-06 味之素株式会社 内酰胺化合物及其药物用途
BRPI0407303A (pt) * 2003-02-07 2006-02-07 Ajinomoto Kk Composição farmacêutica
CA2544310A1 (en) 2003-10-31 2005-05-12 Ajinomoto Co., Inc. New fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof
EP1707567A4 (de) * 2004-01-14 2009-08-19 Ajinomoto Kk Neue verbindung mit kondensiertem ring
DK1802625T3 (da) * 2004-10-13 2008-09-01 Hoffmann La Roche Disubstituerede pyrazolobenzodiazepiner der er nyttige som inhibitorer af CDK2 og angiogenese og til behandling af bryst-, tyktarms-, lunge- og prostatacancer
CN101166742B (zh) * 2005-04-28 2011-07-13 味之素株式会社 新型内酰胺化合物
JP5672699B2 (ja) 2007-04-11 2015-02-18 味の素株式会社 血糖降下作用化合物のスクリーニング法
WO2008139574A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
WO2008136393A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
WO2008139575A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. 経口投与用製剤
CN101619041B (zh) * 2008-07-02 2012-07-04 重庆华邦制药股份有限公司 一种二酮基含氮环化合物的合成方法及其中间体
JP2012180282A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
JP2012180283A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
US20170369494A1 (en) * 2014-12-22 2017-12-28 Ea Pharma Co., Ltd. Drug for treating disorders of corneal epithelium
WO2017127306A1 (en) 2016-01-18 2017-07-27 Arisan Therapeutics Adamatane derivatives for the treatment of filovirus infection
WO2019018185A1 (en) 2017-07-15 2019-01-24 Arisan Therapeutics Inc. ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
SG11202106694YA (en) * 2019-01-23 2021-07-29 Glycolysis Biomed Co Ltd Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US189597A (en) * 1877-04-17 Improvement in portable wash-stands
US48847A (en) * 1865-07-18 Improvement in vessels for reception and transportation of night-soil
GB8720414D0 (en) * 1987-08-28 1987-10-07 Roussel Lab Ltd Chemical compounds
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
JP2001512120A (ja) 1997-07-30 2001-08-21 アメリカン・ホーム・プロダクツ・コーポレイション 三環系バソプレシンアゴニスト
JP4204657B2 (ja) 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
CN100577651C (zh) * 2000-12-01 2010-01-06 味之素株式会社 内酰胺化合物及其药物用途
BRPI0407303A (pt) 2003-02-07 2006-02-07 Ajinomoto Kk Composição farmacêutica

Also Published As

Publication number Publication date
US7153850B2 (en) 2006-12-26
ES2331299T3 (es) 2009-12-29
WO2002044180A1 (en) 2002-06-06
CA2430124A1 (en) 2002-06-06
DE60140270D1 (de) 2009-12-03
AU1850202A (en) 2002-06-11
EP1346993A4 (de) 2005-12-21
JPWO2002044180A1 (ja) 2004-04-02
KR100826818B1 (ko) 2008-05-02
JP3826400B2 (ja) 2006-09-27
NZ526164A (en) 2004-09-24
NO325401B1 (no) 2008-04-21
EP1346993A1 (de) 2003-09-24
JP2006213732A (ja) 2006-08-17
EP1346993B1 (de) 2009-10-21
CN1487940A (zh) 2004-04-07
ATE446297T1 (de) 2009-11-15
UA76969C2 (en) 2006-10-16
HUP0400806A3 (en) 2007-11-28
NO20032439D0 (no) 2003-05-28
AU2002218502B2 (en) 2006-09-21
TWI241302B (en) 2005-10-11
US20080096862A1 (en) 2008-04-24
CZ20031520A3 (cs) 2003-10-15
RU2287530C2 (ru) 2006-11-20
US7632830B2 (en) 2009-12-15
AU2006241377A1 (en) 2006-12-14
CA2430124C (en) 2011-01-11
MXPA03004876A (es) 2004-01-27
SK6582003A3 (en) 2003-09-11
BG107857A (bg) 2004-06-30
KR20030051893A (ko) 2003-06-25
NO20032439L (no) 2003-07-18
US7326701B2 (en) 2008-02-05
US20060189597A1 (en) 2006-08-24
PL362835A1 (en) 2004-11-02
YU42603A (sh) 2006-03-03
AU2006241377B2 (en) 2009-01-08
ZA200304100B (en) 2004-08-22
CN1269818C (zh) 2006-08-16
CN1911915A (zh) 2007-02-14
JP4505753B2 (ja) 2010-07-21
CN100577651C (zh) 2010-01-06
BR0115852A (pt) 2003-12-23
US20040048847A1 (en) 2004-03-11
HUP0400806A2 (hu) 2004-07-28

Similar Documents

Publication Publication Date Title
AU1850202A (en) Lactam compounds and medicinal use thereof
WO2000041681A3 (de) ARZNEIFORMULIERUNGEN ENTHALTEND EIN OPIOID UND EINEN α-AGONISTEN
CA2386690A1 (en) Pharmaceutical tramadol salts
WO2003084520A3 (en) Pharmaceutical preparation containing oxycodone and naloxone
AU2001276689A1 (en) Novel remedies for cancer
HUP0204170A3 (en) 5-thia-omega-substituted phenyl-prostaglandin e derivatives, process for producing the same and drugs containing the same as the active ingredient
HUP0400155A3 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
MXPA03003029A (es) Combinaciones de productos activos con propiedades insecticidas, fungicidas y acaricidas.
AU2002238855A1 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
MXPA04002510A (es) Combinacion de opioides selectos con antagonistas de muscarina para tratamiento de incontinencia urinaria.
AU2001228811A1 (en) Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient
ZA200309232B (en) Active ingredient combination for treating a dependence on addictive substances or narcotics using medicaments.
WO2001039723A3 (en) Triazospiro compounds having nociceptin receptor affinity
WO2003082926A3 (en) Antimicrobial polymer conjugates
WO2002053090A3 (fr) Association medicamenteuse d'une biguanine (metformine) et d'arginine
EP0953355A4 (de) Heilmittel für autoimmunkrankheiten
AU2001258443A1 (en) Drug delivery device, especially for the delivery of gestodene
AU1650501A (en) 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient
TW200509980A (en) Parasiticidal composition
WO2003011247A3 (de) Trägermatrix mit wirkstoffbeladenen partikeln zur anwendung auf der haut oder schleimhaut
WO2001060398A8 (en) Drugs for ameliorating impaired glucose tolerance
EP1234834A4 (de) Derivate des 1,3,4-oxadiazolin-2-on und medikamente, die diese derivate als aktive substanzen enthalten
WO2001037818A3 (de) Medikament sowie aufeinander abgestimmte kombination von medikamenten
WO2002024210A3 (en) Halogen compounds for use in medicine
AU2001241067A1 (en) Omega-substituted phenyl-prostaglandin e-alcohols, process for producing the same and drugs containing the same as the active ingredient